Exonics Therapeutics Stock

Developer of gene repair therapies designed for devastating genetic neuromuscular diseases. The company's uses CRISPR/Cas9 technology which is a potential one-time treatment that would make a permanent correction of the mutation that causes Duchenne by identifying and correcting exon mutations that prevent the production of dystrophin, a protein that helps stabilize and protect muscle fibers, enabling patients to improve their lives and have a lifelong benefit.